4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)
Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet
26
Participants partenaires
TERMINÉ
Decision-making within cells and differentiation entity therapies (DECIDE)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
"Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiat ...
Voir le projet
8
Participants partenaires
TERMINÉ
European Paediatric Oncology Off-Patent Medicines Consortium (EPOC)
Date du début: 1 févr. 2009, Date de fin: 31 oct. 2013,
Cancer chemotherapy has a key role in the successful treatment of a number of childhood cancers. Nevertheless, at least 20% of patients are not cured by current therapies and a significant number experience debilitating toxicities. Given the high cure rates and potential life-span of survivors of childhood cancer, it is particularly important to minimize the impact of potential chronic toxicities. ...
Voir le projet
11
Participants partenaires
TERMINÉ
Oral Off-patent Oncology Drugs for Kids (03K)
Date du début: 1 sept. 2008, Date de fin: 31 août 2011,
"There is an urgent need for appropriate oral formulations of anticancer drugs for the treatment of paediatric malignancies in children. The goal of the O3K consortium is to develop oral liquid formulations of Cyclophosphamide and Temozolomide, important chemotherapeutics which have been identified in the list of paediatric needs by EMEA (EMEA/197972/2007). Both off-patent drugs are widely used or ...
Voir le projet